Cite
MLA Citation
M Reck et al.. “1386PDIMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC.” Annals of oncology, vol. 29, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100095508705.0x000026